During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- Patient age influences response to immunotherapy for melanoma on October 5, 2018 at 9:10 am
Age should be a consideration when predicting response to immunotherapy for melanoma, according to study results published in Clinical Cancer Research. Patients aged older than 60 years responded more ... […]
- Immunotherapy combination at MD Anderson Cancer Center shows promise for HPV-related cancers on October 5, 2018 at 7:43 am
The combination of two therapies that enlist the patient’s immune system showed promise against incurable cancers caused by the sexually transmitted HPV virus, according to a small Houston study that ... […]
- Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth on October 5, 2018 at 6:00 am
According to data compiled by Transparency Market Research, the global cancer immunotherapy market is expected to grow from USD 37.50 Billion in 2015 to USD 124.88 Billion by 2024 while registering a ... […]
- Synthetic DNA-encoded checkpoint inhibitor antibodies advance cancer immunotherapy on October 4, 2018 at 4:11 pm
Scientists demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that ... […]
- Cancer immunotherapy sweeps Nobel for medicine on October 4, 2018 at 11:40 am
Fittingly, James Allison heard the news at a conference of the very field his work helped launch. At a New York City hotel where he was staying for a meeting on cancer immunotherapy, Allison, an immun... […]
- Immunotherapy Continues to Be Integrated in Metastatic Bladder Cancer on October 4, 2018 at 7:07 am
An FDA safety warning suggests that the role of immunotherapy in the treatment of patients with metastatic bladder cancer may need altering, explained Peter O’Donnell, MD, an associate professor of me... […]
- Cancer Immunotherapy Market 2018 Global Demand Analysis | Industry to Touch $101.6 Billion till 2023 | Exclusive Revelation by MRFR on October 4, 2018 at 4:16 am
This report studies the Cancer Immunotherapy Market outlook of Global Market 2018. The Cancer Immunotherapy Market report investigates vital information that assists Industry professionals. Report pro... […]
- Immunotherapy: 'Killer' cells get boost in fight against cancer on October 4, 2018 at 12:46 am
Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current lis... […]
- Treating Lung Cancer with Immunotherapy: How These Groundbreaking Drugs Work on October 3, 2018 at 10:04 am
Getting a lung cancer diagnosis is a scary and overwhelming experience. You probably have many questions about your condition, in hopes to find answers to what may seem like an endless amount of unkno... […]
- Immunotherapy is advancing cancer treatment on October 2, 2018 at 7:27 pm
When someone receives a cancer diagnosis, he/she often feels overwhelmed. I have been in this position when my family member was diagnosed with cancer. The experience I had while taking care of my lov... […]
via Google News and Bing News